Recruiting

PRP with Clitoral Injections

Sponsor:

Medstar Health Research Institute

Code:

NCT07948915

Conditions

Sexual Function

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Accepted

Interventions

Platelet-Rich Plasma (PRP) Injections

Study Details

Brief summary:

The goal of this clinical trial is to learn if adding platelet-rich plasma (PRP) injections near the clitoris improves sexual function more than PRP injections in the vaginal wall alone. The study includes sexually active adults who were assigned female at birth. PRP is made from a person's own blood. It contains growth factors that may help tissue heal and renew.

The main questions it aims to answer are:

Does adding PRP near the clitoris improve sexual function 6 weeks after treatment, compared with vaginal wall PRP alone? Do any improvements last at 3 and 6 months? How painful are the injections, and what side effects do participants have?

Researchers will compare two groups. All participants will get PRP injected into the front wall of the vagina. One group will also get PRP injected near the clitoris. The other group will get a placebo (sham) injection near the clitoris: the needle goes under the skin, but nothing is injected. Participants will not know which group they are in.

Participants will:

Answer questionnaires about their health and sexual function before treatment. Come to one in-person visit, about 1 hour long. At this visit they will have blood drawn to make the PRP and receive the injections.

Rate their pain shortly after the injections. Complete 3 short online follow-up visits at 6 weeks, 3 months, and 6 months. At these visits they will answer questionnaires about sexual function and side effects.

Conditions

Sexual Function

Study ID

NCT07948915

Start date

Nov 1, 2026

Status verified date

Oct, 2026

Completion date

May 1, 2028

Anticipated

Primary completion date

Nov 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Adults 18 years of age or older who were assigned female at birth
  • Sexually active, with at least one episode of sexual activity (alone or with a partner) in the past month
  • English speaking
  • Able to complete study questionnaires
  • Willing to undergo blood draw and genital injection procedure

Exclusion Criteria:

  • Pregnant, suspected pregnancy, or breastfeeding/lactating
  • Active infection
  • Autoimmune condition
  • History of pelvic radiation
  • History of pelvic malignancy
  • Current use of anticoagulant medication
  • Prior urogenital platelet-rich plasma injection
  • History of female genital mutilation/cutting
  • Presence of urethrovaginal mesh (including midurethral sling)
  • Chronic or acute pelvic pain preventing pelvic examination
  • Active genital infection

Study Design

Enrollment

58 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

sham comparator: Anterior Vaginal Wall PRP + Periclitoral Sham

All participants in this arm will receive active PRP injection into the anterior vaginal wall; they will receive a sham injection into the peri-clitoral sites.

experimental: Anterior Vaginal Wall PRP + Periclitoral PRP

All participants in this arm will receive active PRP injection into the anterior vaginal wall; they will receive active PRP injection into the peri-clitoral sites.

Interventions

Platelet-Rich Plasma (PRP) Injections

A single treatment session. 40-60 mL of autologous whole blood is processed with the Arthrex Angel system (15-minute centrifugation), yielding approximately 2-4 mL of leukocyte-rich platelet-rich plasma (PRP), which is used within 2 hours of preparation. After topical anesthesia, all participants receive two-thirds of the PRP volume injected superficially into the distal anterior vaginal wall, approximately 3 cm from the urethral meatus, using a 28-32 gauge needle.

Experimental arm: The remaining PRP (approximately 1 mL) is delivered as two superficial injections of about 0.5 mL each near the junction of the clitoris, clitoral hood, and frenulum.

Sham comparator arm: A needle is inserted at the same peri-clitoral sites without injecting any substance.

Participants are blinded to peri-clitoral assignment.

Primary outcome measure

  • Change in Female Sexual Function Index Total Score [ Time Frame: Baseline and 6 weeks after treatment ]

Central Contacts and Locations

Central contacts

Locations

MedStar Health at Lafayette Centre

Recruiting

Washington D.C., District of Columbia, United States, 20036

Contacts

More Information

Sponsor

Medstar Health Research Institute

Last update posted

Nov 19, 2026

Last verified

Oct, 2026

Keywords

  • Platelet-Rich Plasma
  • Sexual Dysfunction
  • Clitoris
  • Vagina
  • Orgasm
  • Libido
  • Regenerative Medicine
  • Women's Health
  • Female sexual function
  • Female Sexual Function Index

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Medstar Health Research Institute on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.